cgs 10746b has been researched along with apomorphine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boja, JW; Schechter, MD | 1 |
Altar, CA; Kim, HS; Wood, PL | 1 |
2 other study(ies) available for cgs 10746b and apomorphine
Article | Year |
---|---|
CGS 10746B is able to attenuate the effects of amphetamine: further evidence for dopaminergic mediation.
Topics: Alkaloids; Animals; Antipsychotic Agents; Apomorphine; Cocaine; Conditioning, Operant; Dextroamphetamine; Discrimination, Psychological; Dopamine; Dose-Response Relationship, Drug; Male; Rats; Thiazepines | 1988 |
Presynaptic inhibition of nigrostriatal dopamine release in the mouse: lack of cross tolerance between apomorphine, GBL and CGS 10746B.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Animals; Apomorphine; Corpus Striatum; Dopamine; Drug Tolerance; Efferent Pathways; Furans; Male; Mice; Substantia Nigra; Thiazepines | 1988 |